

Can Consensus in Single Antigen Testing be Achieved?


Amy Hahn, PhD, D(ABHI)

Albany Medical College




Albany, NY



How can you agree that a test result is clinically relevant if you can't agree on the test result?



Sources of Variability in HLA Antibody Detection - Cellular




<p>cell panel composition linkage disequilibrium number of washes autoantibodies condition of cells effects of drugs*</p>	<p>same as for CDC but also: source and lot of AHG can't use AHG for B cells</p>	<p>Fc receptors pronase – HLA expression serum:cell ratio condition of cells effects of drugs* variability in cytometers, fluorochromes, reagents</p>
---	--	---

*steroids, rituximab, IVIg, ATG, etc.


Sources of Variability in HLA Antibody Detection – Solid Phase

ELISA




antigen source
antigen density
Ig isotype and subclass
interfering factors*
no single antigen for
class II – linkage
disequilibrium

Flow Bead Array




epitopes spread across a
few beads
antigen source
Ig isotype and subclass
interfering factors*
manual vs automation
number of washes
serum:bead ratio
variable antigen density

Luminex Bead Array



epitopes spread across many beads
denatured antigen
interfering factors*
latex antibodies
antigen source
Ig isotype and subclass
manual vs automation
number of washes
serum:bead ratio
variable antigen density on bead
exaggerated antigen density
DQA and DPA chain effects

*IgM, complement C1, immune complexes, IVIg



<u>Serum date</u>	<u>dMCF(T/B)</u>	<u>dMESF(T/B)</u>
pre-txp	10 / 20	537 / 548
day 7 post-txp	281 / 294	32,389 / 66,439

Influence of Test Technique on Sensitization Status of Patients on the Kidney Transplant Waiting List.

tested pretransplant sera of 534 patients using CDC, ELISA and SAB (1λ)

Table 1: Detection of HLA antibodies using different test techniques in patients on the kidney transplant waiting list

	Positive patients							
	CDC	ELISA			ELISA or CDC	SAB		
		Class I	Class II	Class I or II		Class I	Class II	Class I or II
All patients ¹ (n = 534)	28 (5%)	48 (9%)	54 (10%)	73 (14%)	78 (15%)	392 (73%)	246 (46%)	435 (81%)
Without history of immunization (n = 133)	2 (2%)	0 (0%)	1 (1%)	1 (1%)	3 (2%)	93 (70%)	45 (34%)	102 (77%)
With history of immunization (n = 286)	22 (8%)	39 (14%)	47 (16%)	61 (21%)	63 (22%)	221 (77%)	150 (52%)	240 (84%)


¹In 115 patients, the information on immunization history was not available.
Luminex cutoff MFI ≥ 1000 .

antibodies in non-immunized patients:

- 25% >5,000 MFI (up to 14,400)
- some against common antigens (A*2402, B*0801, etc.)
- most not present in SAB assay by other vendor (Lifecodes)
- most not present on PRA bead assay (natural antigens – not recombinant)

Strategies for human leukocyte antigen antibody detection.


8 labs tested one serum by same method, looked at one bead (A*02:01)



Bars indicate the MFI (median fluorescence intensity) reported by each of the eight participating laboratories for the single-antigen bead containing A*0201. Note: although all laboratories agreed on the antigen assignment (HLA- A*02), there was a wide range of values reported.

Inter and intra laboratory concordance of HLA antibody results obtained by single antigen bead based assay.

4 labs used class I and II SAB from a single manufacturer to test 10 patient sera single lot, same SOP, looked at 4 different MFI cutoffs
originating lab also tested same samples on four consecutive days




Standardization of Microparticle-Based, Solid Phase, HLA Antibody Identification Assays

SENDOUT ONE

- 21 Laboratories enrolled (UK, US, France, Germany, Italy) (data from 19 using one vendor)
- Testing performed on 5 well characterized sera using laboratory's standard methods
- First round of data analysis to identify parameters leading to non-consensus

SENDOUT TWO



- fewer labs (N=8) using a standardized protocol and same lot of reagents to test 4 sera



- %CV decreases with standard protocol
- Factors NOT correlating with results:
 - Filter vs flick/spin
 - Washes – 3 to 5; Avg: 3.5
 - serum-to-cell ratio
- still differences between labs
- converting to SFI?
- lower MFI – higher CV

Comprehensive Assessment and Standardization of Solid Phase Multiplex-Bead Arrays for the Detection of Antibodies to HLA.

CTOT: Clinical Trials in Organ Transplantation Antibody Core Laboratories
7 labs used 10 kits from 2 manufacturers to test 20 reference sera



- single SOP reduces variation
- still have manufacturer variation
- most variation at low MFI
- MFI cutoff of 1000-1500 had >90% agreement in antigen assignment
- overall CV=25% {so 50% change in MFI (2xCV) means real change in Ab level}

Antibody Consensus Conference – May 2012 recommendations toward standardization

- standardize critical components
 - HLA source and preparation method
 - panel composition
 - appropriate allele coverage, including DQA, DPA, DPB
 - antigen density on bead
 - antigen integrity
 - native vs denatured
 - anti-human Ig detection reagents

Antibody Consensus Conference – May 2012 recommendations toward standardization

- standardize operating procedure
 - type of plastic trays used
 - V-bottom vs. U-bottom
 - serum volume to bead ratio
 - washing methods
 - spin/flick vs. filter tray
 - vortexing methods
 - unified approach to sample preparation to minimize interference
 - EDTA, DTT, hypotonic dialysis, spin column
 - automated processing equipment

Antibody Consensus Conference – May 2012 recommendations toward standardization

- standardize interpretation and reporting
 - calibration of fluoroanalyzers and flow cytometers using control particles
 - use of standard fluorescent intensity (SFI) and MESF
 - defined reporting algorithms
 - background normalization
 - reports should include assay type, criteria for positive/negative results, Ig isotype, serum modification, factors that affect test values and interpretation

Antibody Consensus Conference – May 2012 recommendations toward standardization

- standardized reference reagents should be developed
 - repository of well-characterized HLA polyclonal and monoclonal reference reagents
 - to all HLA class I and II antigens
 - different titers and isotypes
 - validated in national and international exchange
 - validated on cell panels and solid phase immunoassays
 - validated for all available techniques
 - ongoing technique and reagent validation
 - monitoring interlaboratory variability
 - reproducible quantification of fluorescence values

